Long-term efficacy trajectories of GLP-1 receptor agonists: a systematic review and network meta-analysis, Diabetes, Metabolic Syndrome and Obesity (2025) The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among Type 2 diabetes patients in the United States, Journal of Managed Care & Specialty Pharmacy (2019) Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta-analysis, Obesity (2022) FDA approves first medication for obstructive sleep apnea, U.S
The article treats these as the behaviors built during treatment that have to continue afterward, rather than as something introduced only once the medication stops
Increase your intake of potassium-rich foods: Potassium helps retain water in the stool, alleviating constipation
Although consensus was not consistently achieved regarding the prioritisation of BMI when choosing between SGLT2is and GLP-1 RAs, BMI was still recognised as one of the clinical factors that influences decision-making
Common Hepaglide 0.25 mg injection side effects are: Nausea or vomiting Diarrhea or constipation Abdominal pain or bloating Headache Injection site reactions, such as redness, swelling, or irritation Fatigue or dizziness Safety Advice Liver Disease There is limited information regarding the use of Hepaglide 0.25 mg in patients with liver disease
